Organogenesis Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Organogenesis Holdings wird ein jährliches Gewinn- und Umsatzwachstum von 36.8% bzw. 3.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 34.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -0.8% betragen.

Wichtige Informationen

36.8%

Wachstumsrate der Gewinne

34.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	3.9%
Zukünftige Eigenkapitalrendite	-0.8%
Analystenabdeckung	Low
Zuletzt aktualisiert	17 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Jun 15

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Jun 10

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

May 21

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

May 01

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Apr 10

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Jan 04

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

May 31

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

Jan 19

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Oct 18

The Market Doesn't Like What It Sees From Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Earnings Yet

Mar 31

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Mar 04

Organogenesis Holdings (NASDAQ:ORGO) Seems To Use Debt Quite Sensibly

Nov 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ORGO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	489	12	N/A	40	3
12/31/2025	459	-4	N/A	29	3
12/31/2024	454	-5	N/A	26	3
3/31/2024	435	6	7	26	N/A
12/31/2023	433	5	7	31	N/A
9/30/2023	449	13	-4	28	N/A
6/30/2023	457	10	-19	17	N/A
3/31/2023	461	13	-16	18	N/A
12/31/2022	451	16	-9	25	N/A
9/30/2022	463	59	7	35	N/A
6/30/2022	460	71	23	57	N/A
3/31/2022	462	83	32	65	N/A
12/31/2021	467	94	31	62	N/A
9/30/2021	446	62	36	67	N/A
6/30/2021	433	69	28	48	N/A
3/31/2021	379	43	3	21	N/A
12/31/2020	338	17	-12	5	N/A
9/30/2020	306	-5	-40	-24	N/A
6/30/2020	270	-37	-50	-38	N/A
3/31/2020	266	-42	-51	-41	N/A
12/31/2019	261	-39	-40	-34	N/A
9/30/2019	250	-46	-48	-45	N/A
6/30/2019	236	-48	-65	-62	N/A
3/31/2019	215	-58	-68	-66	N/A
12/31/2018	193	-65	-62	-61	N/A
9/30/2018	183	-60	-48	-46	N/A
6/30/2018	184	-52	-27	-25	N/A
3/31/2018	187	-32	-11	-9	N/A
12/31/2017	199	-9	N/A	-3	N/A
12/31/2016	139	-17	N/A	-5	N/A
12/31/2015	99	-24	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ORGODas prognostizierte Gewinnwachstum (36.8% pro Jahr) liegt über der Sparquote (2.4%).

Ertrag vs. Markt: ORGODie Erträge des Unternehmens (36.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.8% pro Jahr).

Hohe Wachstumserträge: ORGOEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: ORGODie Einnahmen des Unternehmens (3.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ORGODie Einnahmen des Unternehmens (3.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ORGO wird voraussichtlich in 3 Jahren unrentabel sein.

Organogenesis Holdings Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 11% to US$4.17

Consensus EPS estimates fall by 267%

Consensus EPS estimates upgraded to US$0.01 loss

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates fall from profit to US$0.013 loss

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Recent updates

We Think Organogenesis Holdings Inc.'s (NASDAQ:ORGO) CEO Compensation Package Needs To Be Put Under A Microscope

Price target decreased by 11% to US$4.17

Consensus EPS estimates fall by 267%

Organogenesis Holdings: Small-Cap Biotech With Inconsistent Earnings And A Powerful Catalyst

Investors Can Find Comfort In Organogenesis Holdings' (NASDAQ:ORGO) Earnings Quality

Investor sentiment improves as stock rises 25%

Consensus EPS estimates upgraded to US$0.01 loss

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings released: US$0.016 loss per share (vs US$0.023 loss in 1Q 2023)

Organogenesis Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

Shareholders Should Be Pleased With Organogenesis Holdings Inc.'s (NASDAQ:ORGO) Price

Organogenesis Holdings Inc., Annual General Meeting, Jun 20, 2024

Investor sentiment deteriorates as stock falls 20%

Organogenesis Holdings Inc. to Report Q1, 2024 Results on May 09, 2024

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Organogenesis Announces Favorable Court Ruling Dismissing Securities Fraud Case

Chief Operating Officer exercised options to buy US$432k worth of stock.

Consensus EPS estimates fall from profit to US$0.013 loss

New minor risk - Earnings quality

Full year 2023 earnings: EPS and revenues miss analyst expectations

Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024

Investor sentiment improves as stock rises 20%

Organogenesis Holdings Inc. to Report Q4, 2023 Results on Feb 29, 2024

Insider recently sold US$77k worth of stock

Investor sentiment improves as stock rises 17%

These 4 Measures Indicate That Organogenesis Holdings (NASDAQ:ORGO) Is Using Debt Reasonably Well

Investor sentiment improves as stock rises 22%

Consensus forecasts updated

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment deteriorates as stock falls 15%

High number of new directors

Organogenesis Holdings Inc. to Report Q3, 2023 Results on Nov 09, 2023

Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023

Investor sentiment deteriorates as stock falls 20%

Investor sentiment improves as stock rises 16%

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Organogenesis Holdings Inc. to Report Q2, 2023 Results on Aug 09, 2023

Investor sentiment deteriorates as stock falls 15%

Is Organogenesis Holdings (NASDAQ:ORGO) Using Too Much Debt?

Investor sentiment improves as stock rises 23%

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year 2023

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Investor sentiment improves as stock rises 16%

Insider recently sold US$104k worth of stock

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorates as stock falls 17%

Organogenesis Holdings Inc. to Report Q4, 2022 Results on Mar 01, 2023

Does Organogenesis Holdings (NASDAQ:ORGO) Have A Healthy Balance Sheet?

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.098 in 3Q 2021)

Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Organogenesis: Finding A Spot For This Regenerative Medicines Company In My 'Bio Boom' Portfolio

Organogenesis Holdings Inc. to Report Q3, 2022 Results on Nov 09, 2022

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Investor sentiment deteriorated over the past week

Organogenesis Receives FDA Clearance for Next Generation PuraPly Surgical Solution

Organogenesis gets FDA clearance for PuraPly MZ for wound healing

Organogenesis Holdings Inc. Provides Earnings Guidance for the Fiscal Year Ending December 31, 2022

Second quarter 2022 earnings: EPS misses analyst expectations

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Has Caught The Eye Of Investors

President exercised options to buy US$2.5m worth of stock.

Organogenesis Holdings Inc. to Report Q2, 2022 Results on Aug 09, 2022

Insider recently sold US$923k worth of stock

Here's Why Organogenesis Holdings (NASDAQ:ORGO) Can Manage Its Debt Responsibly

Insider recently bought US$60k worth of stock

Organogenesis Holdings: What Now

Consensus forecasts updated